# Progress Note 04 — Focused Visit (Follow-up)

> **SYNTHETIC RECORD, NOT A REAL MEDICAL RECORD**

- Patient: Clara Barton (real historical name used in a fictional teaching record)
- Synthetic MRN: HR-NI024-SYN-TD
- Date: 1874-04-14
- Fictional facility: St. Posthumous Health Center
- Fictional author: Eleanor Whitcombe, MD
- Calendar frame: true historical dates (modern content is anachronistic)

> True-date frame: synthetic events are moved into the patient's historical lifetime. Codes, instruments, and treatments remain modern and are anachronistic.

- Visit type: Focused Visit (Follow-up)

## Chief complaint

Twelve-week depression treatment review. **S**

## History of present illness

Ms. Barton returns six weeks after sertraline was increased to 100 mg. At the nurse telephone check two weeks after the increase she reported three days of mild nausea and no restlessness or suicidal thoughts. She now has more good days than bad, enjoys her work again, and sleeps about six and a half hours. She has had ten CBT sessions and is using the sleep schedule. She increased to 35 hours a week after the last visit and this week to her new limit of 45 hours, and she has handed the families' correspondence to a colleague. She has missed no doses and has had no side effects since the first few days after the increase. She has had no suicidal thoughts. **S**

| Element | Detail |
|---|---|
| Interval change | More good days than bad; enjoying work again |
| Dose increase | Three days of mild nausea after the increase; nurse check at two weeks with no concerns |
| Sleep | About six and a half hours |
| Work | Up to 45 hours a week; correspondence delegated |
| Safety | No suicidal thoughts |
| PHQ-9 | 7, down from 18 |

## Review of systems

| System | Result | Finding |
|---|---|---|
| Constitutional | Negative | Energy better; weight up 1.1 kg since intake |
| Gastrointestinal | Negative | No nausea now; no bleeding |
| Genitourinary | Negative | No sexual side effects |
| Psychiatric | Positive | Mild residual low energy on some days; no suicidal thoughts, elevated mood, or racing thoughts |

4 systems reviewed. **S**

## Current medications

- Sertraline 100 mg oral tablet, one tablet by mouth each morning **S**

## Allergies

- No known allergy **S**

## Objective

BP 118/74 mmHg; pulse 72 bpm; respirations 14/min; temperature 36.6 °C; oxygen saturation 99% on room air; weight 50.9 kg; BMI 22 kg/m². All vital signs are synthetic.

PHQ-9: 7; GAD-7: 4. All results are synthetic.

## Change since baseline

- PHQ-9: 18 at baseline, 7 at this visit **S**
- GAD-7: 9 at baseline, 4 at this visit **S**

## Physical examination

| System | Finding |
|---|---|
| General | Well groomed; brisk |
| Mental status | Alert; mood "much better"; affect reactive with humor; thought process linear; no suicidal ideation; insight and judgment good |

All examination findings are synthetic. **S**

## Assessment and plan

1. **Major depressive disorder, recurrent, responding** (F33.1). PHQ-9 7, down 61 percent from 18: a response, not yet remission. GAD-7 4. Sleep at goal. Suicide risk remains low. **S**
   - Continue sertraline 100 mg.
   - Care-manager telephone PHQ-9 in about four weeks, then a review in two months.
   - Continue CBT to the end of the course.
   - Collaborative safety plan reviewed and unchanged; 988 Suicide & Crisis Lifeline and the clinic number confirmed.
2. **Occupational burnout** (Z73.0). Back at full duties within the 45-hour limit. **S**
   - Keep the 45-hour limit; join the relief workers' peer support group; no deployment for at least six months.

## Protocol monitoring

Items the monitoring protocol calls for at this visit. **S**

| Domain | Measure | Interval | Status | Detail |
|---|---|---|---|---|
| Survey | PHQ-9 | Baseline, then at least monthly during acute treatment; every 2 to 4 weeks in continuation | Completed today | 7, down 61 percent from 18: response; remission not yet reached |
| Survey | GAD-7 | With the PHQ-9 when anxiety symptoms were present at baseline | Completed today | 4, down from 9 |
| Survey | Suicide risk reassessment (C-SSRS Since Last Visit and PHQ-9 item 9) | Every visit during active treatment | Completed today | No suicidal thoughts, intent, plan, or behavior since the last visit; PHQ-9 item 9 scored 0. Safety plan reviewed |
| Medication safety | Tolerability check two weeks after the dose increase | 2 weeks after each dose change | Completed today | Done by nurse telephone call two weeks after the increase: three days of mild nausea, no activation or suicidal thoughts |
| Medication safety | Adherence and adverse-effect review | Every visit during active treatment | Completed today | No missed doses; no side effects now |
| Self-management | Psychotherapy, sleep, work hours, and social contact | Every visit during active treatment | Completed today | Ten CBT sessions; sleep about six and a half hours; 45-hour week; peer support group advised |
| Laboratory | Lithium, anticonvulsant, or antipsychotic monitoring (levels, metabolic tests, AIMS) | Only on those drugs | Not indicated | Treated with an SSRI only |

## Goal progress

- Response (PHQ-9 down by at least 50 percent) by twelve weeks. Outcome by 1874-04-14: PHQ-9 7 at twelve weeks, down 61 percent from 18. **S**
- Remission (PHQ-9 below 5) and continuation treatment for at least twelve months after remission. In progress; target 1874-06-16. **S**
- Sleep at least six hours most nights. Outcome by 1874-04-14: About six and a half hours most nights by twelve weeks. **S**
- Phased return to work at no more than 45 hours a week, with no field deployment for at least six months. In progress; target 1874-06-16. **S**
- Time with friends or her faith community at least twice a week. In progress; target 1874-06-16. **S**

## Guideline basis

- VA/DoD Clinical Practice Guideline for the Management of Major Depressive Disorder (2022), United States Department of Veterans Affairs and Department of Defense
- VA/DoD Clinical Practice Guideline for Assessment and Management of Patients at Risk for Suicide (2024), United States Department of Veterans Affairs and Department of Defense
- CMID: Clinical Monitoring Intelligence Database, depression, bipolar, and mood disorders monograph (2026), Aether Forge

## Follow-up

- Care-manager telephone PHQ-9 in about four weeks; depression review in two months. **S**
- Next scheduled visit 1874-06-16: five-month depression review in continuation treatment. **S**
